Brown 1998.

Study characteristics
Methods	Parallel design Analysis: per protocol: 1 withdrawn (treatment), excluded from analysis
Participants	Diagnosis: stroke, time from stroke to randomisation not reported Randomised 10 to treatment and 10 to control Treatment: 9 completed treatment, mean ± SD age 61.4 ± 8.6 years, 55% men Control: 10 people completed placebo, mean ± SD age 63.7 ± 5.4 years, 60% men Emotionalism criteria: emotionalism of at least 4 weeks' duration assessed during semi‐structured interview using a modified Lawson and MacLeod rating scale, in addition to frequency of outbursts Exclusion criteria: cognitive impairment, dysphasia, major depressive disorder
Interventions	Treatment: fluoxetine 20 mg daily Control: matched placebo Duration: 10 days Duration of follow‐up: (end of treatment to end of study) 0
Outcomes	Used leaving the study early Unable to use data from HDRS, Lawson and MacLeod Scale, self‐rating scales (mean and SD not presented) Also reported emotional outbursts; we have not used these in our analyses AEs: not presented
Funding source	Funder not stated
Notes	Dates of study not stated; conflicts of interest not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated
Allocation concealment (selection bias)	Unclear risk	Randomised by independent statistician
Blinding of participants and personnel (performance bias) All outcomes	Low risk	States blinding of patients and nursing staff, matched placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	States blinding of rating clinicians
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 1 withdrawn (5% of participants); we categorised this as low risk
Selective reporting (reporting bias)	Unclear risk	Insufficient information to make judgement
Other bias	Low risk	No other obvious biases, baseline balanced